Jilin Province Huinan Changlong Bio-pharmacy Company Limited (HKG:8049)

Market Cap	896.40M
Revenue (ttm)	937.70M
Net Income (ttm)	196.07M
Shares Out	560.25M
EPS (ttm)	0.35
PE Ratio	4.57
Forward PE	n/a
Dividend	0.07 (4.15%)
Ex-Dividend Date	Jun 18, 2024

Volume	420,000
Average Volume	146,300
Open	1.650
Previous Close	1.670
Day's Range	1.600 - 1.670
52-Week Range	1.210 - 1.850
Beta	0.29
RSI	48.69
Earnings Date	Mar 28, 2025

About HKG:8049

Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People’s Republic of China. It offers Edaravone injection, compound brain comfort capsules, haikun kidney hi capsules, cefpirome sulfate for injections, Cefpiramide for injections, anti-bone hyperplasia tablets, Lysine glucosa tablets, prostate laurel yellow tablets, tranquility tablets, pharyngitis tablets, and low back pain capsules. The company markets its products under the Changlon...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 745
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 8049

Financial Performance

In 2024, HKG:8049's revenue was 881.16 million, an increase of 4.71% compared to the previous year's 841.55 million. Earnings were 184.25 million, an increase of 24.32%.

Financial numbers in CNY